TBX-3400 / Taiga Biotech - LARVOL DELTA

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Taiga Biotechnologies, Inc.; Phase classification: P1 ➔ P1/2; N=20 ➔ 60; Trial completion date: Apr 2022 ➔ Apr 2023; Trial primary completion date: Jan 2022 ➔ Jan 2023

Clinical • Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CD69